Tag Archives: Spain

Type 2 Diabetes Opportunities in Europe "Vast", Says Report

“Vast” Diabetes Opportunities in Europe, Says Report The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan. The International Diabetes Federation states that more than 55 million people have been diagnosed with […]
Posted in Europe, healthcare | Also tagged , , , , , , , | Leave a comment

Orphan Drug Adoption: the More Regulation, the Better

New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks. In his study, ‘The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries,’ John Matthews, Associate Director of […]
Posted in Europe, Global, Market Access, Orphan Drugs, pricing, Regulatory | Also tagged , , , , , | Leave a comment

Spanish Generics Industry to Government: "Leave Branded Pharma Alone"

Just days before the reports that R&D investment in Spanish pharma had fallen to below EUR1 billion ($1.3 billion) in 2011 for the first time since 2007, the country’s generic manufacturers association, AESEG, offered some unexpected support for the branded industry. In comments to APM Health Europe described as “rare”, AESEG chief Ángel Luis Rodríguez […]
Posted in Europe, Global, healthcare | Also tagged , , , , , | Leave a comment

The Pain in Spain

The pain of the Spanish drug-spending squeeze extends way beyond the plain, says Reflector. The cries of anguish at Spanish drug-spending squeezes are coming not only from Madrid, but from many of the autonomous regions around the periphery of the country too. After almost a decade of continual disruption and downward pressure on pricing, the […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , | 2 Comments

Europe’s Fiscal Crisis: Can Big Pharma Emerge Unscathed?

Europe’s current fiscal crisis, symbolized by the meltdown in Greece, is seen by big pharma as a temporary situation to be taken in stride—after all, the EU southern and eastern tier, with its chronically shaky finances and per capita incomes as low as a third of the EU norm, has historically been a marginal player […]
Posted in Europe | Also tagged , , , , , | 2 Comments
  • Categories

  • Meta